17β-Estradiol enhances breast cancer cell motility and invasion via Extra-Nuclear activation of Actin-Binding protein ezrin

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Zheng, Shuhui ^a   Huang, Jinghe ^a   Zhou, Kewen ^a   Zhang, Chengxi ^b   Xiang, Qiuling ^a   Tan, Zhi ^a   Wang, Tinghuai ^a   Fu, Xiaodong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ESTRADIOL; ESTROGEN RECEPTOR; EZRIN; FULVESTRANT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RHO KINASE; RHO KINASE 2; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; THREONINE; UNCLASSIFIED DRUG; WORTMANNIN; ACTIN BINDING PROTEIN; CYTOSKELETON PROTEIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; ROCK2 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DRUG TARGETING; ESTROGEN ACTIVITY; NUCLEOTIDE SEQUENCE; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL MOTION; CELL NUCLEUS; CYTOSKELETON; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; HUMAN; INTRACELLULAR SPACE; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

BREAST NEOPLASMS; CELL MOVEMENT; CELL NUCLEUS; CYTOSKELETAL PROTEINS; CYTOSKELETON; ENZYME ACTIVATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; INTRACELLULAR SPACE; MICROFILAMENT PROTEINS; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 79960753506     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022439     Document Type: Article

References (66)

1. Verkooijen HM, Bouchardy C, Vinh-Hung V, Rapiti E, Hartman M, (2009) The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. Maturitas 64: 80-85.
2. Russo J, Russo IH, (2006) The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 102: 89-96.
3. Janni W, Hepp P, (2010) Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev 36: 249-261.
4. Kedrin D, van Rheenen J, Hernandez L, Condeelis J, Segall JE, (2007) Cell motility and cytoskeletal regulation in invasion and metastasis. J Mammary Gland Biol Neoplasia 12: 143-152.
5. Louvet-Vallee S, (2000) ERM proteins: from cellular architecture to cell signaling. Biol Cell 92: 305-316.
6. Fu XD, Giretti MS, Baldacci C, Garibaldi S, Flamini M, et al. (2008) Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS ONE 3: e2790.
7. Giretti MS, Fu XD, De Rosa G, Sarotto I, Baldacci C, et al. (2008) Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS ONE 3: e2238.
8. Fu XD, Flamini M, Sanchez AM, Goglia L, Giretti MS, et al. (2008) Progestogens regulate endothelial actin cytoskeleton and cell movement via the actin-binding protein moesin. Mol Hum Reprod 14: 225-234.
9. Simoncini T, Scorticati C, Mannella P, Fadiel A, Giretti MS, et al. (2006) Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol 20: 1756-1771.
10. Berryman M, Franck Z, Bretscher A, (1993) Ezrin is concentrated in the apical microvilli of a wide variety of epithelial cells whereas moesin is found primarily in endothelial cells. J Cell Sci 105 (Pt 4): 1025-1043.
11. Schwartz-Albiez R, Merling A, Spring H, Moller P, Koretz K, (1995) Differential expression of the microspike-associated protein moesin in human tissues. Eur J Cell Biol 67: 189-198.
12. Bruce B, Khanna G, Ren L, Landberg G, Jirstrom K, et al. (2007) Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 24: 69-78.
13. Sarrio D, Rodriguez-Pinilla SM, Dotor A, Calero F, Hardisson D, et al. (2006) Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat 98: 71-79.
14. Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M, (2005) The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 7: R365-373.
15. Fievet BT, Gautreau A, Roy C, Del Maestro L, Mangeat P, et al. (2004) Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin. J Cell Biol 164: 653-659.
16. Cant SH, Pitcher JA, (2005) G protein-coupled receptor kinase 2-mediated phosphorylation of ezrin is required for G protein-coupled receptor-dependent reorganization of the actin cytoskeleton. Mol Biol Cell 16: 3088-3099.
17. Ivetic A, Ridley AJ, (2004) Ezrin/radixin/moesin proteins and Rho GTPase signalling in leucocytes. Immunology 112: 165-176.
18. Ren L, Hong SH, Cassavaugh J, Osborne T, Chou AJ, et al. (2009) The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene 28: 792-802.
19. Chuan YC, Pang ST, Cedazo-Minguez A, Norstedt G, Pousette A, et al. (2006) Androgen induction of prostate cancer cell invasion is mediated by ezrin. J Biol Chem 281: 29938-29948.
20. Fu XD, Simoncini T, (2007) Non-genomic sex steroid actions in the vascular system. Semin Reprod Med 25: 178-186.
21. Sandilands E, Akbarzadeh S, Vecchione A, McEwan DG, Frame MC, et al. (2007) Src kinase modulates the activation, transport and signalling dynamics of fibroblast growth factor receptors. EMBO Rep 8: 1162-1169.
22. Greger JG, Fursov N, Cooch N, McLarney S, Freedman LP, et al. (2007) Phosphorylation of MNAR promotes estrogen activation of phosphatidylinositol 3-kinase. Mol Cell Biol 27: 1904-1913.
23. Croft DR, Sahai E, Mavria G, Li S, Tsai J, et al. (2004) Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis. Cancer Res 64: 8994-9001.
24. Yager JD, Davidson NE, (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282.
25. Yamazaki D, Kurisu S, Takenawa T, (2005) Regulation of cancer cell motility through actin reorganization. Cancer Sci 96: 379-386.
26. Kobel M, Langhammer T, Huttelmaier S, Schmitt WD, Kriese K, et al. (2006) Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Mod Pathol 19: 581-587.
27. Kang YK, Hong SW, Lee H, Kim WH, (2010) Prognostic implications of ezrin expression in human hepatocellular carcinoma. Mol Carcinog 49: 798-804.
28. Kim C, Shin E, Hong S, Chon HJ, Kim HR, et al. (2009) Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat 41: 138-144.
29. Bretscher A, Edwards K, Fehon RG, (2002) ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3: 586-599.
30. Li Q, Wu M, Wang H, Xu G, Zhu T, et al. (2008) Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett 261: 55-63.
31. Li J, Tu Y, Wen J, Yao F, Wei W, et al. (2010) Role for ezrin in breast cancer cell chemotaxis to CCL5. Oncol Rep 24: 965-971.
32. Prag S, Parsons M, Keppler MD, Ameer-Beg SM, Barber P, et al. (2007) Activated ezrin promotes cell migration through recruitment of the GEF Dbl to lipid rafts and preferential downstream activation of Cdc42. Mol Biol Cell 18: 2935-2948.
33. Fu XD, Simoncini T, (2008) Extra-nuclear signaling of estrogen receptors. IUBMB Life 60: 502-510.
34. Levin ER, (2009) Plasma membrane estrogen receptors. Trends Endocrinol Metab 20: 477-482.
35. Revelli A, Massobrio M, Tesarik J, (1998) Nongenomic actions of steroid hormones in reproductive tissues. Endocr Rev 19: 3-17.
36. Chien EJ, Morrill GA, Kostellow AB, (1991) Progesterone-induced second messengers at the onset of meiotic maturation in the amphibian oocyte: interrelationships between phospholipid N-methylation, calcium and diacylglycerol release, and inositol phospholipid turnover. Mol Cell Endocrinol 81: 53-67.
37. Song J, Fadiel A, Edusa V, Chen Z, So J, et al. (2005) Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett 220: 57-65.
38. Fadiel A, Lee HH, Demir N, Richman S, Iwasaki A, et al. (2008) Ezrin is a key element in the human vagina. Maturitas 60: 31-41.
39. Chambliss KL, Wu Q, Oltmann S, Konaniah ES, Umetani M, et al. (2010) Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest 120: 2319-2330.
40. Ng T, Parsons M, Hughes WE, Monypenny J, Zicha D, et al. (2001) Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility. EMBO J 20: 2723-2741.
41. Yonemura S, Matsui T, Tsukita S, (2002) Rho-dependent and-independent activation mechanisms of ezrin/radixin/moesin proteins: an essential role for polyphosphoinositides in vivo. J Cell Sci 115: 2569-2580.
42. Planas-Silva MD, Bruggeman RD, Grenko RT, Stanley Smith J, (2006) Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun 341: 73-81.
43. Raz L, Khan MM, Mahesh VB, Vadlamudi RK, Brann DW, (2008) Rapid estrogen signaling in the brain. Neurosignals 16: 140-153.
44. Rahman MA, Senga T, Ito S, Hyodo T, Hasegawa H, et al. (2010) S-nitrosylation at cysteine 498 of c-Src tyrosine kinase regulates nitric oxide-mediated cell invasion. J Biol Chem 285: 3806-3814.
45. Koga F, Xu W, Karpova TS, McNally JG, Baron R, et al. (2006) Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci U S A 103: 11318-11322.
46. Chan TO, Rodeck U, Chan AM, Kimmelman AC, Rittenhouse SE, et al. (2002) Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell 1: 181-191.
47. Cui Y, Li T, Zhang D, Han J, (2010) Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma. Cancer Invest 28: 242-247.
48. Ju X, Katiyar S, Wang C, Liu M, Jiao X, et al. (2007) Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci U S A 104: 7438-7443.
49. Gautreau A, Poullet P, Louvard D, Arpin M, (1999) Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 96: 7300-7305.
50. Tran Quang C, Gautreau A, Arpin M, Treisman R, (2000) Ezrin function is required for ROCK-mediated fibroblast transformation by the Net and Dbl oncogenes. EMBO J 19: 4565-4576.
51. Rebillard A, Jouan-Lanhouet S, Jouan E, Legembre P, Pizon M, et al. (2010) Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells. Eur J Cancer 46: 1445-1455.
52. Hebert M, Potin S, Sebbagh M, Bertoglio J, Breard J, et al. (2008) Rho-ROCK-dependent ezrin-radixin-moesin phosphorylation regulates Fas-mediated apoptosis in Jurkat cells. J Immunol 181: 5963-5973.
53. Matsui T, Yonemura S, Tsukita S, (1999) Activation of ERM proteins in vivo by Rho involves phosphatidyl-inositol 4-phosphate 5-kinase and not ROCK kinases. Curr Biol 9: 1259-1262.
54. Lee JH, Katakai T, Hara T, Gonda H, Sugai M, et al. (2004) Roles of p-ERM and Rho-ROCK signaling in lymphocyte polarity and uropod formation. J Cell Biol 167: 327-337.
55. Srivastava J, Elliott BE, Louvard D, Arpin M, (2005) Src-dependent ezrin phosphorylation in adhesion-mediated signaling. Mol Biol Cell 16: 1481-1490.
56. Heiska L, Carpen O, (2005) Src phosphorylates ezrin at tyrosine 477 and induces a phosphospecific association between ezrin and a kelch-repeat protein family member. J Biol Chem 280: 10244-10252.
57. Wang Q, Pfeiffer GR 2nd, Gaarde WA, (2003) Activation of SRC tyrosine kinases in response to ICAM-1 ligation in pulmonary microvascular endothelial cells. J Biol Chem 278: 47731-47743.
58. Sanchez AM, Flamini MI, Baldacci C, Goglia L, Genazzani AR, et al. (2010) Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol 24: 2114-2125.
59. Migliaccio A, Castoria G, Di Domenico M, Ciociola A, Lombardi M, et al. (2006) Crosstalk between EGFR and extranuclear steroid receptors. Ann N Y Acad Sci 1089: 194-200.
60. Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, et al. (2003) Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Res 63: 5203-5208.
61. Etique N, Grillier-Vuissoz I, Flament S, (2006) Ethanol stimulates the secretion of matrix metalloproteinases 2 and 9 in MCF-7 human breast cancer cells. Oncol Rep 15: 603-608.
62. Takei H, Lee ES, Jordan VC, (2002) In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer 9: 39-42.
63. Applanat MP, Buteau-Lozano H, Herve MA, Corpet A, (2008) Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression. Adv Exp Med Biol 617: 437-444.
64. Bendrik C, Dabrosin C, (2009) Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol 182: 371-378.
65. Lin Y, Huang R, Chen L, Li S, Shi Q, et al. (2004) Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 109: 507-515.
66. Grem JL, Geoffroy F, Politi PM, Cuddy DP, Ross DD, et al. (1995) Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells. Mol Pharmacol 48: 305-315.